10-Q: AXIM Biotechnologies Reports Q2 2024 Results: Revenue Increases but Losses Persist

AXIM Biotechnologies saw revenue growth in Q2 2024 compared to the previous year, but continues to operate with a significant net loss and negative working capital.

Summary

• AXIM Biotechnologies, Inc. filed its Form 10-Q for the quarterly period ended June 30, 2024.
• The company reported revenues of $17,479 for the three months ended June 30, 2024, compared to $9,929 for the same period in 2023.
• For the six months ended June 30, 2024, revenues were $70,458, up from $17,078 in the prior year period.
• The company's net loss for the three months ended June 30, 2024, was $2,269,815, compared to a net loss of $3,723,295 for the same period in 2023.
• The net loss for the six months ended June 30, 2024, was $2,562,114, compared to a net loss of $6,485,923 for the same period in 2023.
• The company has negative working capital of $6,552,128 and an accumulated deficit of $74,746,972.
• The company's strategic focus is on commercializing FDA-cleared Dry Eye Disease (DED) diagnostic system.
• The company intends to file for a CLIA waiver in the third quarter of 2024.
• The company is developing a novel tear sample collector system and filed for a patent.
• The company aims to reach a positive cash flow run rate by the end of 2024.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While revenue is increasing and losses are decreasing, the company still faces significant financial challenges, including negative working capital and an accumulated deficit. The focus on the DED market and the development of new diagnostic tools are positive signs, but the company's ability to achieve profitability remains uncertain.

Positives

• Revenue increased for both the three and six months ended June 30, 2024, compared to the same periods in 2023.
• Net loss decreased for both the three and six months ended June 30, 2024, compared to the same periods in 2023.
• The company is focused on commercializing its FDA-cleared Dry Eye Disease (DED) diagnostic system.
• The company is developing a novel tear sample collector system and filed for a patent.
• The company intends to file for a CLIA waiver in the third quarter of 2024.
• The company aims to reach a positive cash flow run rate by the end of 2024.

Negatives

• The company has negative working capital of $6,552,128.
• The company has an accumulated deficit of $74,746,972.
• The company is still operating at a net loss.
• The company's ability to continue as a going concern is dependent on its ability to generate future profitable operations and/or obtain necessary financing.

Risks

• The company's ability to continue as a going concern is dependent on its ability to generate future profitable operations and/or obtain necessary financing.
• The company may not be able to meet its contractual obligations.
• The company may not be able to maintain its staff at current levels.
• The company faces intense competition in the biotechnology and pharmaceutical industries.
• The company is subject to extensive government regulation.
• The company is exposed to market risks, including the potential for growth in new markets being uncertain.
• The company is exposed to the effects of inflation.

Future Outlook

The company plans to focus on commercializing its FDA-cleared Dry Eye Disease (DED) diagnostic system and aims to reach a positive cash flow run rate by the end of 2024.

Management Comments

• The company believes it is well positioned to dominate the DED marketplace.
• The company believes that the acquisition of these FDA 510(k) cleared diagnostic products, a waiver and the distribution partnership we have with Versea will allow the business to grow at a rapid pace.

Industry Context

The report highlights AXIM's focus on the Dry Eye Disease (DED) market, which is a growing area within ophthalmology. The company is positioning itself to compete with existing diagnostic tests and treatments for DED.

Comparison to Industry Standards

• The report mentions Quidel's InflammaDry test as a competitor in the MMP-9 testing space, but highlights AXIM's development of a quantitative test as a potential advantage.
• The report notes that there are currently five FDA approved tests for DED.
• The report mentions TearLab's Osmolarity test as a competitor in the DED diagnostic market.

Legal Proceedings

• The company has entered into a Settlement Agreement with the Plaintiffs manager to fully resolve the matter in its entirety.
• Effective February 7, 2024, the Company entered into a confidential Global Settlement Agreement Pursuant to the Settlement, the Company agreed to pay the following compensation to IMS: a total cash payment of $100,000 payable in various payments over a 24 month period; a $0.35 cassette sales participation payment on all single dry eye lateral flow test cassettes sold by the Company up to a total of $475,000, with such payments having no limit as to the time it takes to reach $475,000; and the issuance of 20,000,000 restricted shares of Company common stock.

Related Party Transactions

• The Company has an employment agreement with Catalina Valencia at a rate of $15,000 per month commencing March 17, 2020.
• The Company has a consulting agreement with Glycodots LLC whereby it will provide the services of Dr. Sergei A. Svarovsky at a rate of $15,000 per month commencing March 17, 2020.
• The company entered into a Convertible Note Purchase Agreement (CNPA) with its affiliated shareholder, Medical Marijuana, Inc.
• As of December 31, 2023, the Company owed to the Executive, for employment in his capacity as CEO of AXIM, $512,500 of unpaid salary which is overdue and payable immediately.

Stakeholder Impact

• Shareholders: The company's financial performance and strategic decisions will impact shareholder value.
• Employees: The company's ability to maintain staff levels and provide compensation is dependent on its financial performance.
• Customers: The company's focus on commercializing its DED diagnostic system will impact the availability of diagnostic tools for eye care professionals.
• Suppliers: The company's supply agreements will impact the demand for raw materials and manufacturing services.
• Creditors: The company's ability to repay its liabilities is dependent on its financial performance and ability to raise capital.

Next Steps

• The company intends to file for a CLIA waiver in the third quarter of 2024.
• The company intends to run a clinical study for MMP-9 in the 1st quarter of 2025.
• The company plans to conduct a comparative clinical study commencing with Lactoferrin.
• The company aims to reach a positive cash flow run rate by the end of 2024.

Key Dates

Keywords

Dry Eye Disease, DED, Diagnostic, Lactoferrin, IgE, MMP-9, Revenue, Net Loss, Biotechnology, Pharmaceutical, FDA, CLIA, Financial Results